Study identification

PURI

https://redirect.ema.europa.eu/resource/31045

EU PAS number

EUPAS17985

Study ID

31045

Official title and acronym

A prediction model for future exacerbation risk in children

DARWIN EU® study

No

Study countries

United Kingdom

Study description

Asthma attacks in children are common and result in considerable morbidity and occasionally mortality. Additionally, childhood asthma attacks may adversely affect their education, their parents economic productivity and always incur costs to the healthcare system. Remarkably little is understood about factors which predict childhood asthma attacks and much of what is known is derived from relatively small clinical trials in countries other than the UK and the results may not be generalisable. The present analysis will use routinely acquired data collected in primary care in the UK to identify factors associated with asthma attacks in children. Predictive variables will include demographics (the child’s age and sex), asthma characteristics (severity, control and past attacks) and physiological measurements (obesity, lung function and blood eosinophil count). Blood and airway eosinophilia are both risk factors for asthma attacks in adults and whilst the latter would be preferable, this is not routinely collected whereas blood eosinophil count is often measured and is used in this analysis.

Study status

Finalised
Research institution and networks

Institutions

Networks

Respiratory Effectiveness Group (REG)
Belgium
Denmark
France
Germany
Greece
Hungary
Italy
Netherlands
Spain
Sweden
United Kingdom
First published:
04/06/2024
Network
ENCePP partner

Contact details

Steve Turner

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Other

More details on funding

Respiratory Effectiveness Group
Study protocol
Initial protocol
English (434.4 KB - PDF)View document
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable